Grant K. Goodman
YOU?
Author Swipe
View article: P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Interleukin (IL)-6 receptor blockade with the monoclonal antibody tocilizumab (TCZ) is an established strategy for the management of cytokine release syndrome (CRS…